UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
This document sets out Rwanda's Maternal, Neonatal Child Health (MNCH) national strategy (July 2013- June 2018). The MNCH strategy provides a framework for addressing maternal, neonatal and child health challenges currently facing Rwanda. It is an overarching strategy for scale up of the national re...sponse to reduce the current levels of maternal, neonatal and child mortality and morbidity in line with the
MDG health related targets and HSSP III targets. The life cycle approach and continuum of care concept, starting with care from the home environment to health facility, guided the development of this roadmap. It aims also to maintain and expand the coverage of cost effective and high impact interventions for maternal, neonatal and child survival in order to achieve national and international targets.
more
The Toolkit is a resource that may be used by businesses of all sizes in the different sectors. The guidelines provided in the Toolkit are intentionally general so they can easily be adapted by employers to their specific business culture, working environment and human resource procedures.
The Tool...kit will be particularly relevant to designated employers in terms of the Employment Equity Act 55 of 1998. Human resources personnel, DPO’s and all organisations pursuing greater employment opportunities
for persons with disabilities will find the Toolkit similarly useful.
more
Country update meeting to share lessons, explore opportunities and overcome challenges to scale up: 8-10 June 2010
The Rwandan Health Sector Research Policy (HSRP) policy defines the scope of research in the Rwandan health sector and presents the strategic principles to ensure that the research done in Rwandan health sector will be conducted in a more coordinated manner, promoting research for equity and social ...justice and to benefit the Rwandan community as well as the global community in general. The health sector research policy provides solutions to the challenges which have been identified in health research. It will support and improve Rwanda’s health research environment and create a space and framework in which health research will grow and support improved health outcomes in Rwanda. It gives a clear orientation for dissemination and use of results. For sustainability of health research in Rwanda, foreign researchers are called upon to collaborate with Rwandans with clear capacity building plans.
more
This companion document to Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021-2030 ("the road map") aims to support a range of stakeholders - including countries in which neglected tropical diseases (NTDs) are endemic, international organi...zations and non-State actors - to achieve the road map targets through a transdisciplinary, cross-cutting One Health approach. Specifically, it provides guidance on the One Health actions needed by major stakeholders and how to support a paradigm shift towards One Health in national NTD programmes. Examples of common One Health challenges and how they can be overcome as well as illustrative cases studies are provided throughout. The companion document was developed through a global consultative process involving stakeholder interviews, interactive workshops, and online public consultation.
more
The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death.
The salient observations are as follows:
In 2018, 487 (12.5%) of the... 3906 notified TB patients were tested for RR-TB and only 12 lab confirmed RR-TB patients were initiated on standard MDR-TB treatment of 20-months duration, (a 3-fold increase in RR-TB detection compared with 2017). This amounts to treatment coverage of only 17% of 72 estimated MDR/RR-TB among notified TB patients (3906) and 5% of 240 estimated incident MDR-TB patients as compared to 62% treatment coverage of 6300 incident drug sensitive TB patients estimated in TLS. The treatment success in the 2016 annual cohort of 6 MDR-TB patients has been reported at 83%. 80% of TB patients know their HIV Status with around 1% TB-HIV co-infection, 37/ 77 (48%) TB-HIV Co-infection Detected. Of the 387 PLHIV currently alive on ART, exact status on TB screening and testing is unknown. % of PLHIV newly enrolled in HIV care who received IPT is not known.
In 2018, the mortality rate for TB was 94 deaths per 100,000 people (1200 per annum) in TL with an increasing mortality trend (Figure 1), despite TB services being available for nearly two decades.
A survey of catastrophic costs due to TB (2016) highlights that 83% of TB patients are reported to be facing catastrophic costs due to the disease. This is the highest rate in the world.
more
Vulnerable and Marginalized Groups Planning Framework